Status:
TERMINATED
Medical Data Collection in the Formation of Precision Oncology Registry
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Cancer
Eligibility:
All Genders
Brief Summary
In efforts to develop an aggregation point for patient clinical data and data related to DNA sequencing in the Comprehensive Cancer Center, this registry will be developed to provide a comprehensive d...
Detailed Description
PRIMARY OBJECTIVES: I. To capture characteristics of the patient population undergoing next generation deoxyribonucleic acid (DNA) sequencing of their tumor or liquid biopsy for more efficient clinic...
Eligibility Criteria
Inclusion
- • All cancer patients at Wake Forest Baptist Comprehensive Cancer Center and its satellites who are having next generation DNA sequencing ordered/performed on their tumor biopsy or surgically resected tissue and/or blood samples.
Exclusion
- Not applicable
Key Trial Info
Start Date :
May 17 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 11 2024
Estimated Enrollment :
2885 Patients enrolled
Trial Details
Trial ID
NCT03874065
Start Date
May 17 2019
End Date
January 11 2024
Last Update
January 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157